Chronic Inducible Urticaria (CIndU)/Physical Urticaria

1. Zuberbier, T., et al., The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI  guideline for the definition, classification, diagnosis, and management of urticaria. Allergy, 2022. 77(3): p. 734-766. 

2. Kaplan, A.P. and J. Garofalo, Identification of a new physically induced urticaria: cold induced cholinergic urticaria. J Allergy Clin Immunol, 1981. 68(6): p. 438-41. 

3. Kolkhir, P., et al., Urticaria. Nat Rev Dis Primers, 2022. 8(1): p. 61. 

4. Greaves, M., Chronic urticaria. J Allergy Clin Immunol, 2000. 105(4): p. 664-72. 

5. Hirschmann, J.V., et al., Cholinergic urticaria. A clinical and histologic study. Arch  Dermatol, 1987. 123(4): p. 462-7. 

6. Sijapati, N., et al., Exercise-Induced Urticaria: A Rare Case Report. Cureus, 2022. 14(3):  p. e23062. 

7. Volcheck, G.W. and J.T. Li, Exercise-induced urticaria and anaphylaxis. Mayo Clin Proc,  1997. 72(2): p. 140-7. 

8. Kulthanan, K., et al., Food-dependent cold urticaria: A new variant of physical urticaria. J Allergy Clin Immunol Pract, 2018. 6(4): p. 1400-1402. 

9. Magerl, M., et al., The definition, diagnostic testing, and management of chronic  inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations  2016 update and revision. Allergy, 2016. 71(6): p. 780-802. 

10. Warin, R.P., Factitious urticaria: red dermographism. Br J Dermatol, 1981. 104(3): p. 285-8. 

11. Lyons, A.B., et al., Successful treatment of solar urticaria with UVA1 hardening in three  patients. Photodermatol Photoimmunol Photomed, 2019. 35(3): p. 193-195. 

12. Perez-Ferriols, A., Barnadas, M., Gardeazabal, J. et al, Solar urticaria: Epidemiology and clinical phenotypes in a Spanish series of 224 patients. Academia Espanola de  Dermatologia Y Venereologia, 2016. 108(2): p. 132-139. 

13. Kulthanan, K., et al., Vibratory Angioedema Subgroups, Features, and Treatment: Results  of a Systematic Review. J Allergy Clin Immunol Pract, 2021. 9(2): p. 971-984. 

14. Mellerowicz, E.J., et al., Angioedema frequently occurs in cholinergic urticaria. J Allergy  Clin Immunol Pract, 2019. 7(4): p. 1355-1357 e1. 

15. Rothbaum, R. and J.S. McGee, Aquagenic urticaria: diagnostic and management  challenges. J Asthma Allergy, 2016. 9: p. 209-213. 

16. Gabrielli, S., et al., Case of postural urticaria in a 14-year-old girl. BMJ Case Rep, 2021.  14(10).

17. Hirohata, A., et al., Unique case of postural cholinergic urticaria induced by a standing  position. Clin Exp Dermatol, 2016. 41(4): p. 439-40. 

18. McManus, N.M., et al., Anaphylaxis Caused by Swimming: A Case Report of Cold induced Urticaria in the Emergency Department. Clin Pract Cases Emerg Med, 2021.  5(3): p. 307-311. 

19. Bayle, P., et al., Localized aquagenic urticaria: efficacy of a barrier cream. Contact  Dermatitis, 2003. 49(3): p. 160-1. 

20. Toth-Kasa, I., et al., Involvement of sensory nerve endings in cold and heat urticaria. J  Invest Dermatol, 1983. 80(1): p. 34-6. 

21. Maurer, M., et al., Omalizumab treatment in patients with chronic inducible urticaria: A  systematic review of published evidence. J Allergy Clin Immunol, 2018. 141(2): p. 638- 649. 

22. Nettis, E., et al., Desloratadine in combination with montelukast suppresses the  dermographometer challenge test papule, and is effective in the treatment of delayed  pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol,  2006. 155(6): p. 1279-82. 

23. Wong, E., et al., Beneficial effects of danazol on symptoms and laboratory changes in  cholinergic urticaria. Br J Dermatol, 1987. 116(4): p. 553-6. 

24. Kulthanan, K., et al., Treatments of cold urticaria: A systematic review. J Allergy Clin  Immunol, 2019. 143(4): p. 1311-1331.

25. Navarro-Trivino FJ, et al. Treatment of refractory solar urticaria: could dupilumab fill the current gap? J Dtsch Dermatol Ges. 2023;21(6):652–3. 10.1111/ddg.15025

26. Marchal V, Reguiai Z. Efficacity of dupilumab in severe idiopathic cold urticaria: a case report. J Dermatolog Treat. 2023;34(1):2182620. 10.1080/09546634.2023.2182620

27. Jasper Therapeutics, Inc. A study of briquilimab in participants with chronic spontaneous urticaria (CSU). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05976243. Published July 31, 2023. Updated February 21, 2024.

28. Terhorst-Molawi D, et al. Anti-KIT antibody barzolvolimab reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78(5):1269–79. Findings from this study show that mast cells are indispensible for the development of SD and ColdU. 10.1111/all.15585 

29. Celldex Therapeutics. A study to evaluate the efficacy and safety of barzolvolimab in chronic spontaneous urticaria. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05960708. Published July 27, 2023. Updated February 26, 2024.